Lymphoma, B-Cell
"Lymphoma, B-Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
| Descriptor ID |
D016393
|
| MeSH Number(s) |
C04.557.386.480.150 C15.604.515.569.480.150 C20.683.515.761.480.150
|
| Concept/Terms |
Lymphoma, B-Cell- Lymphoma, B-Cell
- Lymphoma, B Cell
- B-Cell Lymphoma
- B Cell Lymphoma
- B-Cell Lymphomas
- Lymphomas, B-Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphoma, B-Cell".
Below are MeSH descriptors whose meaning is more specific than "Lymphoma, B-Cell".
This graph shows the total number of publications written about "Lymphoma, B-Cell" by people in this website by year, and whether "Lymphoma, B-Cell" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 2 | 0 | 2 | | 2002 | 2 | 2 | 4 | | 2003 | 1 | 1 | 2 | | 2004 | 2 | 0 | 2 | | 2005 | 2 | 1 | 3 | | 2006 | 4 | 0 | 4 | | 2007 | 2 | 2 | 4 | | 2009 | 4 | 0 | 4 | | 2010 | 1 | 2 | 3 | | 2011 | 2 | 1 | 3 | | 2012 | 4 | 0 | 4 | | 2013 | 5 | 1 | 6 | | 2014 | 2 | 1 | 3 | | 2015 | 2 | 0 | 2 | | 2016 | 2 | 0 | 2 | | 2017 | 4 | 1 | 5 | | 2018 | 5 | 1 | 6 | | 2019 | 5 | 0 | 5 | | 2020 | 5 | 0 | 5 | | 2021 | 4 | 0 | 4 | | 2022 | 13 | 0 | 13 | | 2023 | 9 | 0 | 9 | | 2024 | 3 | 2 | 5 | | 2025 | 6 | 2 | 8 | | 2026 | 5 | 1 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Lymphoma, B-Cell" by people in Profiles.
-
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Altahan A, Andreadis B, Bartlett NL, Budde LE, Caimi PF, DeVos S, Dholaria B, Fayad LE, Gaballa S, Habermann TM, Hernandez-Ilizaliturri F, Hu B, Kamdar M, Karimi Y, Kelsey CR, King R, Kline J, Krivacic S, LaCasce AS, Landsburg D, Lim M, Messmer M, Pophali P, Rabinovitch R, Ramakrishnan P, Reid E, Riedell P, Roberts KB, Saha A, Saito NG, Sawalha Y, Smith SD, Swinnen LJ, Tuscano J, Vose JM, Dwyer M, Sundar H. B-Cell Lymphomas, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2026 Sep; 24(9).
-
Bock AM, Feng L, Chauhan A, Falchi L, Merryman R, Godbole S, Thiruvengadam SK, Jallouk AP, Major A, D'Angelo C, Ayers A, Baron K, Farahat OM, Shouse G, Danilov A, Bair S, Lunning M, Bhaskar S, Herrera AF, Sawalha Y, Flowers CR, Crombie JL, Salles G, Epperla N, Ahmed S. Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab. Blood Adv. 2026 08 25; 10(16):5496-5504.
-
Hill KK, Barry AP, Reinoso-Vizcaino NM, Haynes LE, Bonglack EN, Ferreira DF, Miller SE, Hirschey MD, Chiang LW, Remiszewski S, Luftig MA. SIRT2 deacylase modulators control B cell metabolic reprogramming in EBV infection and mitogenic activation. Proc Natl Acad Sci U S A. 2026 Sep; 123(35):e2532225123.
-
Karulkar A, Jain H, Sidharthan N, Bhurani D, Melinkeri S, Boyella PK, Mehta P, Kaul E, Shah S, P K J, Nair C, Bhargava R, Bagal B, Nayak L, Shetty A, Menon H, Boya RR, Abhinav R, Kalra D, Ravikumar S, Thorat J, Purwar S, Shah NN, Fry T, Jain N, Neelapu S, Sengar M, Purwar R. Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety. Blood Cancer J. 2026 Jul 16; 16(1).
-
Bair SM, Pinto N, Roth A, Verneris M, Haverkos B, Nicklawsky A, Ohm A, Jordan K, Murphy LA, Marians R, Mallo R, Orentas R, Adams C, Kamdar M, Fry T. Feasibility and Safety of a Novel CD19-Directed CAR T-Cell Therapy in Patients with R/R B-Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2026 Oct; 32(10):1268.e1-1268.e12.
-
Okcu I, Wang Y, Li Z, White LJ, Johnston PB, Rosenthal AC, Paludo J, King RL, Witzig TE, Habermann TM, Nowakowski GS, Tun HW. Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL). Hematol Oncol. 2026 Mar; 44(2):e70182.
-
Lee HS, Huh G, Cho H, Jang S, Vargo J, Edmundowicz S, Yoon DH, Park DH. Real-world outcomes of endoscopic ultrasound-guided tissue acquisition for actionable diagnosis in suspected primary or recurrent lymphoma. Gastrointest Endosc. 2026 07; 104(1):33-42.e3.
-
Hess B, Moskowitz A, Davis JA, Strati P, Sawalha Y, Bakos J, Sorrell M, Ferreira AC, Escribano-Serrat S, De Castro M, Brooks TR, Hill BT, Shah GL, Falade AS, Merryman R, Kamdar M, Ip A, Nachar V, Bennett JG, Lux N, Ahmed N, Hoffmann M, LaCasce A. Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R. Haematologica. 2026 04 01; 111(4):1389-1395.
-
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Karimi Y, Kelsey CR, King R, Kline J, Krivacic S, LaCasce AS, Landsburg D, Lim M, Messmer M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Saito NG, Smith SD, Swinnen LJ, Tuscano J, Vose JM, Dwyer M, Sundar H. NCCN GuidelinesĀ® Insights: B-Cell Lymphomas 3.2025. J Natl Compr Canc Netw. 2025 10; 23(10).
-
Porche K, King RL, Habermann TM, Johnston PB, Spinner RJ. Low-Grade B-Cell Neurolymphomatosis: A Case Series and Diagnostic Insight. World Neurosurg. 2025 Sep; 201:124260.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|